GENE ONLINE|News &
Opinion
Blog

2023-03-14| Special

Biotech Start-ups May Face a Foreboding Prospect Following Silicon Valley Bank (SVB)’s Unsuspected Collapse

by Richard Chau
Share To
Silicon Valley Bank (SVB), the 16th largest bank in the United States with total assets of $209 billion and deposits of $175.4 billion (as of the end of 2022), has recently suffered a major financial meltdown, as its shares plummeted precipitously and about $42 billion in deposits were withdrawn in a run. Despite selling its assets and stocks immediately to raise the necessary funds, SVB failed to save itself and went bankrupt last week. As a result, the bank was taken over by the Federal Deposit Insurance Corporation (FDIC).

The collapse of SVB is the largest failure of a financial institution in the United States since the 2008 financial crisis (and the second largest ever). According to SVB, nearly half of all venture-backed technology and biotech start-ups in the U.S. have opened accounts with the bank, amounting to approximately $342 billion in client funds and involving approximately $74 billion in loans. Therefore, the incident is bound to create a substantial impact on the global biotech industry, especially those venture-backed companies.

It's free! Log in now to read

LATEST
Sanofi and Regeneron’s Dupixent Approved as First-in-World Treatment For Uncontrolled COPD
2024-07-04
Advancements in Alzheimer’s Disease Drug Innovation and Funding Programs in 2024
2024-07-04
FDA Greenlights Eli Lilly’s Groundbreaking Alzheimer’s Drug Kisunla for Early Symptomatic Treatment
2024-07-04
BIO Asia–Taiwan 2024 Set to Showcase Global Biotech Industry Talent on July 24th
2024-07-03
Novo Nordisk’s CLARION-CKD Trial Shut Down After Unsuccessful Results Causing Impairment Loss
2024-07-03
Tanvex BioPharma Secures Asia’s First FDA Approval for Filgrastim Biosimilar, Seizing a $403 Million Market
2024-07-03
Ginkgo Job Cuts Expected to Affect at Least 35% of Workforce, Eliminating Over 400 Jobs
2024-07-02
EVENT
Scroll to Top